{"id":25345,"date":"2016-05-04T10:02:37","date_gmt":"2016-05-04T17:02:37","guid":{"rendered":"http:\/\/lifeboat.com\/blog\/2016\/05\/biogen-haemophilia-spin-out-to-develop-gene-therapies-and-long-acting-factors"},"modified":"2017-04-24T21:01:00","modified_gmt":"2017-04-25T04:01:00","slug":"biogen-haemophilia-spin-out-to-develop-gene-therapies-and-long-acting-factors","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2016\/05\/biogen-haemophilia-spin-out-to-develop-gene-therapies-and-long-acting-factors","title":{"rendered":"Biogen haemophilia spin-out to develop gene therapies and long-acting factors"},"content":{"rendered":"<p style=\"padding-right: 20px\"><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/biogen-haemophilia-spin-out-to-develop-gene-therapies-and-long-acting-factors.jpg\"><\/a><\/p>\n<p>The new entity will focus on a haemophilia pipeline utilising the XTEN half-life extension technology, bispecific antibodies and gene therapies.<\/p>\n<p>Biogen announced yesterday it is planning to spin-out its haemophilia business into an independent, public firm based in Boston, Massachusetts by early next year.<\/p>\n<p>Management said during a conference call this was the right time for a spin-out as Biogen\u2019s haemophilia business has matured.<\/p>\n<p><!-- Link: <a href=\"http:\/\/www.in-pharmatechnologist.com\/Drug-Delivery\/Biogen-spin-out-to-focus-on-haemophilia-therapies\">http:\/\/www.in-pharmatechnologist.com\/Drug-Delivery\/Biogen-sp...-therapies<\/a> --><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The new entity will focus on a haemophilia pipeline utilising the XTEN half-life extension technology, bispecific antibodies and gene therapies. Biogen announced yesterday it is planning to spin-out its haemophilia business into an independent, public firm based in Boston, Massachusetts by early next year. Management said during a conference call this was the right time [\u2026]<\/p>\n","protected":false},"author":395,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[43,269],"tags":[],"class_list":["post-25345","post","type-post","status-publish","format-standard","hentry","category-business","category-life-extension"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/25345","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/395"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=25345"}],"version-history":[{"count":2,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/25345\/revisions"}],"predecessor-version":[{"id":50607,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/25345\/revisions\/50607"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=25345"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=25345"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=25345"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}